We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-5.01%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.85B
AUM Growth
-$933M
Cap. Flow
-$365M
Cap. Flow %
-4.65%
Top 10 Hldgs %
37.02%
Holding
151
New
11
Increased
33
Reduced
26
Closed
20

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$137M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$91.8M
3
AET
Aetna Inc
AET
+$82.5M
4
HUM icon
Humana
HUM
+$78.7M
5
MRK icon
Merck
MRK
+$68M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$146M
2
MOH icon
Molina Healthcare
MOH
+$117M
3
ESRX
Express Scripts Holding Company
ESRX
+$102M
4
IPXL
Impax Laboratories, Inc.
IPXL
+$89.8M
5
ABBV icon
AbbVie
ABBV
+$79.7M

Sector Composition

Rank Sector Weight
1 Healthcare 94.02%
2 Financials 1.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CI icon
126
Cigna
CI
$79.1B
– –
-325,700
Closed -$42.4M
EXEL icon
127
Exelixis
EXEL
$14B
– –
-6,206,300
Closed -$79.4M
MRK icon
128
CALL
Merck
MRK
$325B
– –
-366,800
Closed -$21.8M
QURE icon
129
uniQure
QURE
$2.74B
– –
-489,000
Closed -$3.74M
SAGE
130
DELISTED
Sage Therapeutics
SAGE
– –
-235,400
Closed -$10.8M
SRPT icon
131
Sarepta Therapeutics
SRPT
$1.65B
– –
-261,800
Closed -$16.1M
ITCI
132
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-90,000
Closed -$1.37M
ALPN
133
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-14,750
Closed -$480K
ISEE
134
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-1,166,200
Closed -$53.8M
AGN
135
CALL
DELISTED
Allergan plc
AGN
– –
-50,000
Closed -$11.5M
WCG
136
DELISTED
Wellcare Health Plans, Inc.
WCG
– –
-1,248,000
Closed -$146M
ESRX
137
DELISTED
Express Scripts Holding Company
ESRX
– –
-1,451,900
Closed -$102M
IPXL
138
DELISTED
Impax Laboratories, Inc.
IPXL
– –
-3,787,500
Closed -$89.8M
CGNT
139
DELISTED
Cogentix Medical, Inc.
CGNT
– –
-878,145
Closed -$1.6M
QLTI
140
DELISTED
QLT Inc
QLTI
– –
-500,000
Closed -$1.03M
CYNA
141
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
– –
-499,999
Closed -$20.1M
PTX
142
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
– –
-107,300
Closed -$668K
2 3 4 5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q4 2016 Portfolio in Review

As of Q4 2016, OrbiMed held 151 positions worth $7.85B, down 11% from $8.78B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

OrbiMed withdrew a net $365M in Q4 2016, closing 20 positions and reducing 26 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $146M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in Elevance Health worth $147M.

  • OrbiMed's largest Q4 2016 buy was Elevance Health: 1,021,600 shares worth $147M.
  • OrbiMed added most to Alexion Pharmaceuticals in Q4 2016, an estimated $91.8M increase.
  • OrbiMed's biggest Q4 2016 reduction was Molina Healthcare, cutting an estimated $117M.
  • OrbiMed fully exited Wellcare Health Plans, Inc. in Q4 2016, selling an estimated $146M.
  • OrbiMed's ten largest holdings make up 37% of its $7.85B portfolio in Q4 2016.
  • OrbiMed opened 11 new positions and closed 20 in Q4 2016.
  • OrbiMed's portfolio value fell 11% quarter-over-quarter to $7.85B.

Based on OrbiMed's 13F filing for Q4 2016, filed 14 Feb 2017.